| Description |
Lapatinib-[d4] Ditosylate is the labelled derivative of Lapatinib, which is used as a radiolabelled internal standard. Lapatinib is a dual inhibitor of the EGF receptor (EGFR) and ErbB2. |
| Synonyms |
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl-d4]amino]methyl]-2-furanyl]-4-quinazolinamine,4-methylbenzenesulfonicacid; Lapatinib D4 Ditosylate; Lapatinib-d4 (tosylate); N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl-d4]amino]methyl]-2-furanyl]-4-quinazolinamine,4-methylbenzenesulfonic acid |
| IUPAC Name |
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[(1,1,2,2-tetradeuterio-2-methylsulfonylethyl)amino]methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid |
| Related CAS |
388082-78-8 (unlabelled) 231277-92-2 (unlabelled free base) 1184263-99-7 (free base)
|
| Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
| InChI |
InChI=1S/C29H26ClFN4O4S.2C7H8O3S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19;2*1-6-2-4-7(5-3-6)11(8,9)10/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);2*2-5H,1H3,(H,8,9,10)/i11D2,12D2;; |
| InChI Key |
UWYXLGUQQFPJRI-CBYPSWBPSA-N |
| Purity |
98% by CP; 99% atom D |
| Solubility |
soluble in DMSO |
| Storage |
Store at -20°C |
![Lapatinib-[d4] Ditosylate](https://resource.bocsci.com/structure/2749856-05-9.gif)
